MDMA (“ecstasy”), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat
- 580 Downloads
3,4-Methylenedioxymethamphetamine (MDMA) and methamphetamine (METH) are illicit drugs that are increasingly used in combination. The acute and long-term effects of MDMA/METH combinations are largely uncharacterised.
The current study investigated the behavioural, thermal and neurotoxic effects of MDMA and METH when given alone or in combined low doses.
Male rats received four injections, one every 2 h, of vehicle, MDMA (2.5 or 5 mg/kg per injection), METH (2.5 or 5 mg/kg per injection) or combined MDMA/METH (1.25+1.25 mg/kg per injection or 2+2 mg/kg per injection). Drugs were given at an ambient temperature of 28°C to simulate hot nightclub conditions. Body temperature, locomotor activity and head-weaving were assessed during acute drug administration while social interaction, anxiety-related behavior on the emergence test and neurochemical parameters were assessed 4–7 weeks later.
All treatments acutely increased locomotor activity, while pronounced head-weaving was seen with both MDMA/METH treatments and the higher dose METH treatment. Acute hyperthermia was greatest with the higher dose MDMA/METH treatment and was also seen with MDMA but not METH treatment. Several weeks after drug administration, both MDMA/METH groups, both METH groups and the higher dose MDMA group showed decreased social interaction relative to controls, while both MDMA/METH groups and the lower dose MDMA group showed increased anxiety-like behaviour on the emergence test. MDMA treatment caused 5-HT and 5-HIAA depletion in several brain regions, while METH treatment reduced dopamine in the prefrontal cortex. Combined MDMA/METH treatment caused 5-HT and 5-HIAA depletion in several brain regions and a unique depletion of dopamine and DOPAC in the striatum.
These results suggest that MDMA and METH in combination may have greater adverse acute effects (head-weaving, body temperature) and long-term effects (decreased social interaction, increased emergence anxiety, dopamine depletion) than equivalent doses of either drug alone.
KeywordsMethamphetamine MDMA ecstasy Anxiety 5-HT Dopamine Polydrug use
This work was supported by an NH&MRC grant to Iain S. McGregor and Glenn E. Hunt.
- Australian Bureau of Criminal Intelligence, (2002) Australian Illicit Drug Report 2001–2002. Canberra, Commonwealth of AustraliaGoogle Scholar
- Boys A, Lenton S, Norcross K (1997) Polydrug use at raves by a Western Australian sample. Drug Alcohol Rev 16:227–234Google Scholar
- Brecht ML, von Mayrhauser C (2002) Differences between ecstasy-using and nonusing methamphetamine users. J Psychoact Drugs 34:215–223Google Scholar
- Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300:1093–1100Google Scholar
- McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417–8422Google Scholar
- McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE (2003b) Increased anxiety and “depressive” symptoms months after MDMA (“ecstasy”) in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 168: 465–474CrossRefPubMedGoogle Scholar
- Minium EW, King BM, Bear G (1993) Statistical reasoning in psychology and education, 3rd edn. Wiley, New YorkGoogle Scholar
- Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg’s Arch Pharmacol 367:490–499Google Scholar